-

Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the Jefferies Virtual London Healthcare Conference. Gerald Herman, Chief Financial Officer, will participate in an analyst moderated question and answer session on behalf of the company on Wednesday, November 18, 2020 at 2:05 PM Greenwich Mean Time (9:05 AM Eastern Standard Time).

A live audio webcast of the question and answer session will be available on the Investor Relations section of the Company's website at https://ir.bruker.com . A replay will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the event.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

Industry:

Bruker Corporation

NASDAQ:BRKR
Release Summary
Bruker Corporation to Participate in the Jefferies Virtual London Healthcare Conference
Release Versions
English

Contacts

Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

More News From Bruker Corporation

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enab...

Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticl...

Bruker Announces Quarterly Preferred Stock Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202...
Back to Newsroom